<DOC>
	<DOCNO>NCT00961571</DOCNO>
	<brief_summary>This study patient metastatic colorectal cancer treat chemotherapy cancer . The purpose study find Capecitabine Sunitinib use together improve progression-free survival colorectal cancer . All patient take two medicine ( Sunitinib Capecitabine ) mouth every day cancer get bad .</brief_summary>
	<brief_title>Sunitinib Capecitabine First Line Colon Cancer</brief_title>
	<detailed_description>This single-center , open-label , one-arm study . Patients stratify prior adjuvant therapy ECOG performance status study entry . In study , propose obtain PET scan baseline , 2 week , 8 week 24 week initiation treatment . Response 2 week , 8 week 24 week correlate progression-free survival , overall survival response accord RECIST criterion . We collect plasma urine sample enrol patient four week sunitinib treatment . The sample analyze result correlate patient clinical outcome order explore underlie mechanism sunitinib induced hypertension .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirm , newly diagnose metastatic colorectal cancer Measurable evaluable disease surgical resection curative intent possible No adjuvant chemotherapy within 6 month enrollment No prior sunitinib receptor tyrosine kinase inhibitor 18 year age great Anticipated survival least 6 month Ambulatory ECOG performance status 0 1 able maintain weight Normal organ marrow function Must agree avoid pregnancy father child study participation Ability understand willingness sign write informed consent document Chemotherapy radiotherapy within 6 month enrollment Receiving investigational agent Known untreated brain metastasis , uncontrolled seizure disorder , encephalitis , multiple sclerosis Not able ingest oral medication normal absorption GI tract Uncontrolled hypertension History severe/unstable angina , heart attack , congestive heart failure , transient ischemic attack , stroke within 6 month enrollment Cardiac dysrhythmias History clinically significant bleeding within past 6 month , include gross hemoptysis hematuria , underlie coagulopathy History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month study enrollment Current treatment therapeutic dos coumadin Concurrent malignancy colorectal cancer Known dihydropyrimidine dehydrogenase deficiency Uncontrolled intercurrent illness include ongoing active infection psychiatric illness would limit compliance study requirement . Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>capecitabine</keyword>
</DOC>